Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.3K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

15.4K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.3K
Humoral Immune Responses01:36

Humoral Immune Responses

82.2K
Overview
82.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Pemphigoid gestationis and anti-SAE2-positive inflammatory myopathy without cutaneous involvement following assisted reproductive technology pregnancy: a rare autoimmune association.

Italian journal of dermatology and venereology·2026
Same author

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Acta dermato-venereologica·2026
Same author

Patient phenotyping to guide therapeutic strategies in bullous pemphigoid: towards personalized medicine in autoimmune bullous diseases.

The British journal of dermatology·2026
Same author

Mechanistic insights into emerging therapeutic platforms: The 72<sup>nd</sup> annual Montagna Symposium on the Biology of Skin.

The Journal of investigative dermatology·2026
Same author

Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks from the DUPItaPN Study.

Clinical and experimental dermatology·2026
Same author

Hand Edema and waxy papular eruption: a dermatologic riddle.

Clinical and experimental dermatology·2026

Related Experiment Video

Updated: Dec 6, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.8K

B-cell targeted therapies in pemphigus.

Roberto Maglie1, Emiliano Antiga2, Aimee S Payne3

  • 1Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy - robertomaglie.med@libero.it.

Italian Journal of Dermatology and Venereology
|October 5, 2020
PubMed
Summary

Pemphigus therapies aim to eliminate autoreactive B-cells. Rituximab, a B-cell therapy, is effective but causes infections and relapses, necessitating new treatment strategies for this autoimmune skin disease.

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.6K
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

775

Related Experiment Videos

Last Updated: Dec 6, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.8K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.6K
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

775

Area of Science:

  • Immunodermatology
  • Autoimmune Blistering Diseases

Background:

  • Pemphigus is an autoimmune skin disease caused by autoantibodies against desmoglein proteins.
  • Loss of cell-cell adhesion leads to intraepidermal blisters.

Purpose of the Study:

  • To review the use of rituximab in pemphigus treatment.
  • To discuss emerging B-cell and antibody-directed therapies for pemphigus.

Main Methods:

  • Review of current literature on rituximab therapy for pemphigus.
  • Discussion of ongoing clinical studies for novel pemphigus treatments.

Main Results:

  • Rituximab (anti-CD20 monoclonal antibody) is a frontline therapy for pemphigus.
  • Rituximab depletes both autoreactive and non-autoreactive B-cells, increasing infection risk.
  • Disease relapse is common in rituximab-treated patients.

Conclusions:

  • New therapeutic strategies are needed to overcome rituximab limitations.
  • Investigational therapies targeting B-cells and antibodies show promise for pemphigus management.